Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Axil Capital is a venture capital firm based in Tokyo, Japan, founded in 2017 as a spin-off from Mizuho Securities. The firm specializes in biomedical and healthcare technology investments, aiming to create synergies between Japan's biotechnology ecosystem and global markets. Axil Capital focuses on building companies with long-term value and sustainable returns for its investors.
Axil Capital invests in the life sciences sector, including biopharmaceuticals, platform technologies, medical devices, digital health, and healthcare services. The firm targets early-stage ventures as well as late-stage crossover rounds, aiming to diversify its portfolio across various stages of development.
Notable portfolio companies include Elixiron Immunotherapeutics, recently listed on the Taipei Emerging Market; LinqMed, focused on radiopharmaceutical manufacturing; MabGenesis, developing monoclonal antibody therapeutics for animals; CynosBio, conducting clinical trials for osteoarthritis treatments; and GEXVal, involved in research programs for Parkinson's disease treatments.
Submit your pitch through their website's contact form at [URL]. Ensure your proposal aligns with their focus on life sciences and healthcare technology.
Yes, Axil Capital often leads investment rounds, particularly in early-stage ventures within the life sciences sector.
The firm actively participates in follow-on investments to support portfolio companies as they grow and reach new milestones.
Specific fund size details are not publicly available, but Axil Capital focuses on significant investments across various stages of development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.